Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Avanafil

A phosphodiesterase type 5 (PDE5) inhibitor, from the same family as sildenafil and tadalafil, developed in Japan. It was approved in the United States in 2012 and in Europe in 2013 for erectile dysfunction. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?It is absorbed very quickly: it reaches its peak concentration in the blood about 30-45 minutes after it is taken.

AvanafilGo to the active ingredient →
AvanafilActive ingredientAvanafilCat. No. P-A218-001CAS 330784-47-9
D-ProlinolImpurityD-ProlinolCat. No. P-A218-085CAS 68832-13-3
L-ProlinolImpurityL-ProlinolCat. No. P-A218-087CAS 23356-96-9

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.